Cite
HARVARD Citation
Gupta, N. et al. (2020). Brigatinib Dose Rationale in Anaplastic Lymphoma Kinase–Positive Non‐Small Cell Lung Cancer: Exposure–Response Analyses of Pivotal ALTA Study. CPT: pharmacometrics & systems pharmacology. pp. 718-730. [Online].